Calls

Source: S&P Capital IQ transcripts via Xpressfeed · latest indexed call 2026-05-07 · generated 2026-07-19.

Latest call digest

Maximus, Inc., Q2 2026 Earnings Call, May 07, 2026 · 2026-05-07T13:00:00

Q2 FY2026 call — May 7, 2026. Revenue of $1.31 billion landed in line with plan, with adjusted EBITDA margin of 14.4% and adjusted EPS of $2.07. Two unusual items — a $6.9 million ($0.09) software-asset impairment in U.S. Services and a $4.2 million (~$0.08) discrete R&D tax benefit — effectively offset in adjusted EPS. Management raised the FY2026 adjusted EPS guide for the second consecutive quarter to $8.25–$8.55 (up $0.20), lifted the full-year EBITDA margin guide to ~14.2%, and reiterated revenue of $5.2–$5.35 billion and free cash flow of $450–$500 million. It also raised its near-term EBITDA margin target range to 12%–15% and refreshed a $400 million buyback (≈$111 million repurchased in the quarter, $40 million more after quarter-end). Prepared remarks leaned on technology/AI-driven federal margin gains, fraud/program-integrity positioning, and building HR-1 (Medicaid work-requirement/SNAP) state opportunities, with one arrangement estimated to lift current program revenue by more than 30% and U.S. Services expected to return to mid-single-digit organic growth by Q4.

The Q&A was thin — a single analyst (CJS Securities) — and pressed the softer spots the prepared remarks skated over: an elevated 78-day DSO driven by administrative delays at one major federal customer and its effect on buyback capacity; why federal tech-efficiency gains have not yet reached the U.S. Services margin; the drivers of first-half state revenue declines against the promised Q4 recovery; and the still-undefined VA veterans-exam recompete timeline (contract runs to December 31, 2026, with an Industry Day pending).

Participant coverage from the latest call.

Group	Participants	Count
Management	Operator; James Francis — Vice President of Investor Relations, Maximus, Inc.; David Mutryn — CFO & Treasurer, Maximus, Inc.; Bruce L. Caswell — President, CEO & Director, Maximus, Inc.	4
Analysts	Will Gildea — Equity Research Associate, CJS Securities, Inc.	1

Curated latest-call exchanges; one row per analyst topic.

Analyst	Firm	Topic	What changed in Q&A
Will Gildea	CJS Securities, Inc.	Elevated DSO and buyback capacity	Pressed on the higher DSO and repurchase capacity given cash lumpiness; management attributed it to one major federal customer with complex, retroactive invoicing and expects collections to catch up in Q4.
Will Gildea	CJS Securities, Inc.	HR-1 / SNAP offerings	Asked whether other SNAP solutions are being brought to market; management centered on the Accuracy Assistant tool plus wrapped BPO services and the Medicaid community-engagement (work-requirement) tool.
Will Gildea	CJS Securities, Inc.	State revenue decline vs. Q4 recovery	Asked what drove first-half U.S. Services declines and the basis for Q4 growth confidence; management cited prior-year clinical volumes and state-specific dynamics, with HR-1 activity underpinning the Q4 turn.
Will Gildea	CJS Securities, Inc.	Federal vs. Services margin gap	Asked why efficiency gains lifting U.S. Federal have not yet reached U.S. Services; management cited larger federal contract scale, state caution on AI adoption, patchwork state regulation, and legacy-system integration.
Will Gildea	CJS Securities, Inc.	VA recompete	Asked about VA contract timing, a possible extension, and an upcoming Industry Day; management said no formal rebid timeline has been released and the current contract runs through December 31, 2026.
Will Gildea	CJS Securities, Inc.	Remaining federal tough comps	Asked about further tough federal comparables in the back half; management flagged the prior-year fiscal Q3 clinical-volume surge as a continued tough comp.

Theme tracker

Themes are curator-classified across supplied calls.

Theme	Status	Quarters mentioned	Read-through
HR-1 / Medicaid work requirements & SNAP state opportunity	emerged	Q3 2025, Q4 2025, Q1 2026, Q2 2026	Surfaced as the "Big Beautiful Bill" in August 2025 and has become the central state-side growth catalyst; management frames FY2026 as a shaping year with revenue contribution expected in FY2027 as final regulations solidify.
AI and automation as a margin lever	persisted	Q1 2025, Q3 2025, Q4 2025, Q1 2026, Q2 2026	A recurring and increasingly emphasized driver of U.S. Federal margin expansion; management ties it to decoupling labor from volume and, in Q2 2026, raised the near-term margin target on this basis.
VA / veterans-exam recompete (PACT Act, MDE volumes)	persisted	Q4 2023, Q1 2024, Q2 2024, Q3 2024, Q1 2025, Q3 2025, Q1 2026, Q2 2026	The most consistently pressed topic; the current contract runs to December 31, 2026 and the recompete timeline remains undefined, leaving a large federal program as an open question.
Medicaid redeterminations / unwinding tailwind	dropped	Q3 2023, Q4 2023, Q1 2024, Q2 2024, Q3 2024, Q1 2025	The dominant FY2024 U.S. Services tailwind; management says the effort was complete by FY2025, and it is now absent as a driver and instead a year-over-year comp headwind.
Capital deployment — buybacks and disciplined M&A	persisted	Q4 2024, Q4 2025, Q1 2026, Q2 2026	Repurchases stepped up as management calls the shares undervalued, alongside a stated bias toward federal defense / national-security acquisitions, all within a 2x–3x leverage target.

Guidance ledger

Quotes, calls, and speakers are source-verified; outcomes are curator-classified.

Verbatim guidance	Call	Speaker	Curator outcome	Outcome note
“adjusted EPS is projected to be between $5.70 and $6 per share”	Maximus, Inc., 2024 Earnings Call, Nov 21, 2024 · 2024-11-21T14:00:00	David Mutryn	kept	Initial FY2025 range; raised repeatedly through the year and delivered adjusted EPS of $7.36 for fiscal 2025.
“We believe a reasonable range in the near term is 10% to 13% adjusted EBITDA margin.”	Maximus, Inc., 2024 Earnings Call, Nov 21, 2024 · 2024-11-21T14:00:00	David Mutryn	kept	FY2025 came in at a 12.9% adjusted EBITDA margin, within the range; the target was later raised to 12%–15% in May 2026.
“adjusted EPS is projected to be between $7.95 and $8.25 per share”	Maximus, Inc., Q4 2025 Earnings Call, Nov 20, 2025 · 2025-11-20T14:00:00	David Mutryn	pending	Initial FY2026 guide; subsequently raised to $8.05–$8.35 in February and $8.25–$8.55 in May, with the fiscal year not yet complete.
“Free cash flow for fiscal year 2026 is projected to be between $450 million and $500 million.”	Maximus, Inc., Q4 2025 Earnings Call, Nov 20, 2025 · 2025-11-20T14:00:00	David Mutryn	pending	Reiterated on both the Q1 and Q2 FY2026 calls; delivery hinges on DSO normalizing below 70 days by year-end.
“Our adjusted EPS guidance increases by $0.10 and is now expected to range between $8.05 and $8.35 per share.”	Maximus, Inc., Q1 2026 Earnings Call, Feb 05, 2026 · 2026-02-05T14:00:00	David Mutryn	pending	First FY2026 raise; increased again to $8.25–$8.55 in May 2026.
“Our adjusted EPS guidance increases by $0.20 and is now expected to range between $8.25 and $8.55 per share.”	Maximus, Inc., Q2 2026 Earnings Call, May 07, 2026 · 2026-05-07T13:00:00	David Mutryn	pending	Second consecutive raise; fiscal year ends September 30, 2026.

Q&A pressure map

Question counts and firms are curator tallies; analyst coverage shown above.

Topic	Questions	Firms	Pressure / response
VA / veterans-exam contract and recompete	15	CJS Securities, Inc., Raymond James & Associates, Inc., Research Division, Stifel, Nicolaus & Company, Incorporated, Research Division	Pressed in nearly every call across all three brokers, most recently on rebid timing and a possible extension; management has consistently declined to give a firm recompete timeline.
Margin durability and technology-driven efficiency	12	CJS Securities, Inc., Raymond James & Associates, Inc., Research Division, Stifel, Nicolaus & Company, Incorporated, Research Division	Recurring probing on how sustainable the margin gains are and why they show up in Federal but not yet in U.S. Services.
Medicaid redeterminations / unwinding	9	Stifel, Nicolaus & Company, Incorporated, Research Division, Raymond James & Associates, Inc., Research Division, CJS Securities, Inc.	Heavily pressed through FY2024 as analysts sized the tailwind and its wind-down; faded as the exercise completed.
HR-1 / Big Beautiful Bill / SNAP opportunity sizing	5	CJS Securities, Inc., Raymond James & Associates, Inc., Research Division	Repeated attempts to quantify the state opportunity; management has kept answers qualitative on scope and timing, pointing to FY2027 for revenue.
Cash flow, DSO and buyback capacity	4	CJS Securities, Inc., Raymond James & Associates, Inc., Research Division, Stifel, Nicolaus & Company, Incorporated, Research Division	Pressed on free-cash-flow rhythm and, more recently, elevated DSO and its constraint on repurchases; management ties the drag to one federal customer.

Language shifts

Only language evidence verified against the referenced component is shown.

Observation	Verbatim evidence	Call ID	Component
Management lifted its near-term margin ceiling, signaling greater confidence in the durability of technology-driven gains versus the 10%–13% target set the prior year.	“we are raising our near-term adjusted EBITDA margin target range to 12% to 15%”	1994106528	2
New procurement-risk vocabulary entered the prepared remarks, flagging slower federal awards and rising protests as a timing headwind.	“awards have shifted right, protests have increased, further delaying outcomes”	1994106528	3
Cash-collection caution became a repeated theme, with elevated DSO tied to a single federal customer rather than broad demand.	“ongoing administrative delays at a major federal customer”	1994106528	2

The call history shows a management team that has repeatedly raised earnings guidance on technology-driven margin gains while the top line laps its own FY2024–FY2025 volume surges. For the current debate, the swing factors are the unresolved VA recompete and whether the HR-1 / SNAP state pipeline converts into the FY2027 revenue management keeps promising.